S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet Oncology, vol.15, issue.12, pp.538-548, 2014.
DOI : 10.1016/S1470-2045(14)70442-5

D. Joshua, J. Mehta, and M. Gertz, International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3 A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease?Which is best? Asian Pac, Blood J. Cancer Prev, vol.117, issue.15, pp.4701-4705, 2011.

Y. Lu, J. Chen, W. Lin, J. Liang, H. Wang et al., FDG PET or PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma, Clinical Nuclear Medicine, vol.37, issue.9, pp.833-837, 2012.
DOI : 10.1097/RLU.0b013e31825b2071

P. Salaun, T. Gastinne, E. Frampas, C. Bodet-milin, and P. Moreau, FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma, Haematologica, vol.93, issue.8, pp.1269-1271, 2008.
DOI : 10.3324/haematol.12654

G. Fouquet, S. Guidez, C. Herbaux, Z. Van-de-wyngaert, S. Bonnet et al., Impact of Initial FDG-PET/CT and Serum-Free Light Chain on Transformation of Conventionally Defined Solitary Plasmacytoma to Multiple Myeloma, Clinical Cancer Research, vol.20, issue.12, pp.3254-3260, 2014.
DOI : 10.1158/1078-0432.CCR-13-2910
URL : https://hal.archives-ouvertes.fr/hal-01064578

B. Siontis, S. Kumar, A. Dispenzieri, M. T. Drake, M. Q. Lacy et al., Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy, Blood Cancer Journal, vol.5, issue.10, p.364, 2015.
DOI : 10.1111/bjh.12346

E. Zamagni, C. Nanni, F. Gay, A. Pezzi, F. Patriarca et al., 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, Leukemia, vol.124, issue.2, pp.417-422, 2016.
DOI : 10.1056/NEJMc1310911

V. Ambrosini and G. C. Montini, 11 C-choline vs. 18 F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma, World J. Surg. Oncol, vol.5, p.68, 2007.

T. Cassou-mounat, S. Balogova, V. Nataf, M. Calzada, V. Huchet et al., 18 F-fluorocholine versus 18 F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: A pilot study, Eur. J. Nucl. Med. Mol. Imaging, vol.43, 1995.

C. Lapa, S. Knop, M. Schreder, M. Rudelius, M. Knott et al., et al. 11 C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement, pp.254-261, 2016.

T. Inoue and R. Hirai, Comparison of 11 C-4'-thiothymidine, 11 C-methionine, and 18 F-FDG PET/CT for the detection of active lesions of multiple myeloma, Ann. Nucl. Med. 2015, vol.29, pp.224-232

E. Zamagni, C. Nanni, F. Patriarca, E. Englaro, P. Castellucci et al., A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma, Haematologica, vol.92, issue.1, pp.50-55, 2007.
DOI : 10.3324/haematol.10554

M. Escoffre-barbe and A. Stoppa, Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI, Trial. Blood, vol.124, p.3359, 2009.

T. B. Bartel, J. Haessler, T. L. Brown, J. D. Shaughnessy, F. Van-rhee et al., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, vol.114, issue.10, pp.2068-2076, 2009.
DOI : 10.1182/blood-2009-03-213280

A. Brioli, Prognostic relevance of 18 F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, Blood, vol.118, pp.5989-5995, 2011.

R. Haznedar, S. Z. Ak?, O. U. Akdemir, Z. N. Ozkurt, O. Ceneli et al., Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.3, pp.1046-1053, 2011.
DOI : 10.1007/s00259-011-1738-8

R. Fonti, L. Pace, C. Cerchione, L. Catalano, B. Salvatore et al., 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma, Clinical Nuclear Medicine, vol.40, issue.4, pp.303-308, 2015.
DOI : 10.1097/RLU.0000000000000696

R. Fonti, M. Larobina, S. Del-vecchio, S. De-luca, R. Fabbricini et al., Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma, Journal of Nuclear Medicine, vol.53, issue.12, pp.1829-1835, 2012.
DOI : 10.2967/jnumed.112.106500

S. Z. Usmani, A. Mitchell, S. Waheed, J. Crowley, A. Hoering et al., Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3, Blood, vol.121, issue.10, pp.1819-1823, 2013.
DOI : 10.1182/blood-2012-08-451690

E. Zamagni, C. Nanni, K. Mancuso, P. Tacchetti, A. Pezzi et al., PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma, Clinical Cancer Research, vol.21, issue.19, pp.4384-4390, 2015.
DOI : 10.1158/1078-0432.CCR-15-0396

C. Nanni, E. Zamagni, M. Celli, P. Caroli, V. Ambrosini et al., The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM), Clinical Nuclear Medicine, vol.38, issue.2, pp.74-79, 2013.
DOI : 10.1097/RLU.0b013e318266cee2

B. D. Cheson, R. I. Fisher, S. F. Barrington, F. Cavalli, L. H. Schwartz et al., Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification, Journal of Clinical Oncology, vol.32, issue.27, pp.3059-3067, 2014.
DOI : 10.1200/JCO.2013.54.8800

C. Nanni, E. Zamagni, A. Versari, S. Chauvie, A. Bianchi et al., Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe), European Journal of Nuclear Medicine and Molecular Imaging, vol.11, issue.3, pp.414-421, 2016.
DOI : 10.1007/s00259-015-3200-9

S. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, The Lancet Oncology, vol.17, issue.8, pp.328-346, 2016.
DOI : 10.1016/S1470-2045(16)30206-6

C. Lapa, K. Lückerath, U. Malzahn, S. Samnick, H. Einsele et al., ¹⁸ FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation, Oncotarget, vol.5, issue.17, pp.7381-7391, 2014.
DOI : 10.18632/oncotarget.2290

C. Sachpekidis, H. Goldschmidt, D. Hose, L. Pan, C. Cheng et al., PET/CT studies of multiple myeloma using 18???F-FDG and 18???F-NaF: comparison of distribution patterns and tracers??? pharmacokinetics, European Journal of Nuclear Medicine and Molecular Imaging, vol.43, issue.118, pp.1343-1353, 2014.
DOI : 10.1007/s00259-014-2721-y

C. Sachpekidis, J. Hillengass, H. Goldschmidt, B. Wagner, U. Haberkorn et al., Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.Suppl 1, pp.50-62, 2017.
DOI : 10.1007/s00259-016-3502-6

K. Herrmann, M. Schottelius, C. Lapa, T. Osl, A. Poschenrieder et al., First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease, Journal of Nuclear Medicine, vol.57, issue.2, pp.248-251, 2016.
DOI : 10.2967/jnumed.115.167361

F. Kraeber-bodere, C. Bailly, M. Chérel, and J. Chatal, ImmunoPET to help stratify patients for targeted therapies and to improve drug development, European Journal of Nuclear Medicine and Molecular Imaging, vol.42, issue.12, pp.2166-2168, 2016.
DOI : 10.1007/s00259-016-3442-1

Z. Halime, M. Frindel, N. Camus, P. Orain, M. Lacombe et al., Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative, Org. Biomol. Chem., vol.24, issue.34, pp.11302-11314, 2015.
DOI : 10.1039/C5OB01618E